A prostaglandin analogue (ONO-802) in treatment of missed abortion, intrauterine fetal death and hydatiform mole: a dose-finding trial.

Abstract

Forty-eight patients affected with missed abortion, intrauterine fetal death and hydatiform mole were treated with vaginal suppositories containing 1 mg of 16,16-dimethyl-trans-delta 2-PGE1 methyl ester (ONO-802). The patients were divided into two treatment groups. The first, Group A, was given one vaginal suppository every 3 h to a maximum of five suppositories. The product of conception was expelled in 95.8% of patients. In Group B the maximum number of suppositories was reduced to three. The product of conception was expelled in 100% of cases and the average duration of treatment was similar to that for the first group. Although side-effects were mild in both groups, they were reduced in the patients of Group B.

• Authors: N Garcea, R Dargenio, V Panetta, E Moneta, G Tancredi, A Giannitelli
• Journal: European journal of obstetrics, gynecology, and reproductive biology (Eur J Obstet Gynecol Reprod Biol) Vol. 25 Issue 1 Pg. 15-22 (May 1987) ISSN: 0301-2115 [Print] Ireland
• PMID: 3595971 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Abortifacient Agents
• Abortifacient Agents, Nonsteroidal
• Prostaglandins E, Synthetic
• Suppositories
• gemeprost
• Alprostadil

Topics

• Abortifacient Agents (therapeutic use)
• Abortifacient Agents, Nonsteroidal (adverse effects, therapeutic use)
• Abortion, Missed (drug therapy)
• Administration, Intravaginal
• Adult
• Alprostadil (adverse effects, analogs & derivatives, therapeutic use)
• Dose-Response Relationship, Drug
• Drug Evaluation
• Female
• Fetal Death (drug therapy)
• Humans
• Hydatidiform Mole (drug therapy)
• Middle Aged
• Pregnancy
• Prostaglandins E, Synthetic (adverse effects, therapeutic use)
• Suppositories
• Time Factors
• Uterine Neoplasms (drug therapy)